History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuationXx_NEWLINE_xXHistory of allergic reaction attributed to compounds of similar chemical or biologic composition to the MEK inhibitor, trametinibXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel and/or both platinum-based chemotherapy agents are excluded; patient must be able to receive at least one of the two proposed chemotherapy regimensXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib or bevacizumabXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar composition, including macrolide and ketolide antibiotics, temsirolimus/other mTOR inhibitors, temozolomide or irinotecan are not eligibleXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to LY2606368 or to its formulation are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and/or rhIL-12 or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and ramucirumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs (e.g. cisplatin)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition as the study agentsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)Xx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXPatients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or other agents used in the studyXx_NEWLINE_xXPatients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabineXx_NEWLINE_xXPrior history of allergic reactions to G-CSFXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and atezolizumab; patients with a known hypersensitivity to olaparib or any of the excipients of the productXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to hetIL-15.Xx_NEWLINE_xXHistory of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to the taselisib drug formulation or other agents used in this studyXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to phenelzine or other monoamine oxidase inhibitorsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or trastuzumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, decitabine or SGI-110Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib or docetaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to GM-CSFXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sotatercept, lenalidomide, pomalidomide, or dexamethasoneXx_NEWLINE_xXPatients who have any history of allergic reaction(s) attributed to compounds of similar composition to temozolomide, pazopanib, their metabolites, or any component of their formulation are NOT eligible for participationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ficlatuzumab or other agents used in studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and trebananib including history of allergic reactions to bacterially produced proteinsXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PT2385 are ineligibleXx_NEWLINE_xXSubject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to bavituximabXx_NEWLINE_xXPatients with history of allergic reactions attributed to compounds of similar composition to pazopanib, irinotecan, or temozolomide are not eligibleXx_NEWLINE_xXPatients may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to metforminXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib (including abemaciclib)Xx_NEWLINE_xXParticipants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, everolimus or exemestaneXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumabXx_NEWLINE_xXSubjects who have exhibited allergic reactions to tipifarnib, or structural compounds similar to tipifarnib or to its excipients.Xx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib are not eligible; AND/OR patients who have had prior exposure to compounds of similar chemical or biologic composition to palbociclib are not eligible hypersensitivity to any component of palbociclib are not eligible for participationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumabXx_NEWLINE_xXPatient has a history of allergic reactions attributed to perillyl alcohol.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ribociclib, T-DM1 (Cohort A)) and/or trastuzumab (Cohorts B and C) and/or fulvestrant (Cohort C)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX3397 or sirolimusXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinibXx_NEWLINE_xXHistory of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 or paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib (BMN 673) or other agents used in studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, nab-paclitaxel, or other agents used in the study; previous grade 1 or 2 allergic reaction to cetuximab is permissibleXx_NEWLINE_xXHistory of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to tamoxifen, anastrozole, or fulvestrant or any of their ingredientsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimusXx_NEWLINE_xXHistory of allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition to anastrozole or letrozoleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to liposomal cytarabine or other agents used in study inclusive of known allergy to polyethylene glycolXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin and/or rituximabXx_NEWLINE_xXKnown allergy to any of the study agents or to compounds of similar chemical or biologic composition are excluded (including other somatostatin analogs)Xx_NEWLINE_xXHistory of allergic reactions or adverse reactions (e.g., wound dehiscence) attributed to compounds of similar chemical or biologic composition to PLG or known hypersensitivity to GM-CSF, CPG or PLGXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991or other agents used in the studyXx_NEWLINE_xXKnown history of allergic reactions attributed to compounds of similar chemical or biologic composition to fenretinide, such as 13-cis-retinoic acid, retinol, or all-trans-retinoic acidXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib or LY3300054.Xx_NEWLINE_xXSubjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the productXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MCS110, dabrafenib, or trametinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab or nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523Xx_NEWLINE_xXSubjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the productXx_NEWLINE_xXHistory of allergic reactions attributed to compounds, or any of its excipients, of similar chemical or biologic composition to osimertinib or selumetinibXx_NEWLINE_xXHistory of allergic reactions attributed to components of the formulated productXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to chemotherapy to be used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to daratumumabXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumabXx_NEWLINE_xXWomen with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Tamoxifen.Xx_NEWLINE_xXEXPANDED ACCESS COHORT: History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or binimetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide (only for arm B)Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibody treatment, any components used in the ramucirumab drug product (DP) preparation, irinotecan, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to SY-1365Xx_NEWLINE_xXHistory of allergic reactions attributed to cyclophosphamide or alemtuzumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gefitinib or osimertinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to LY3022855, vemurafenib, or cobimetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide or docetaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or previous toxicity attributed to pembrolizumab or other PD-1 directed therapy that led to permanent drug discontinuationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib or olaparibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatinXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970 or irinotecanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib (XL184)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or gemcitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 (onalespib)Xx_NEWLINE_xXPatents with history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to platinum based chemotherapyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or IMGN853Xx_NEWLINE_xXEXCLUSION - INFUSION: History of allergic reactions attributed to nivolumab or any other checkpoint inhibitorsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or venetoclaxXx_NEWLINE_xXKnown hypersensitivity to MK-3475 (pembrolizumab) or history of allergic reactions to compounds of similar chemical or biologic composition to anti-PD1 or PD-L1 antibodies or entinostatXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to HMAsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to merestinibXx_NEWLINE_xXParticipant has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ACTOplus Met XRXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ixazomib or lenalidomideXx_NEWLINE_xXParticipant with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoidsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib.Xx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone or paclitaxel/nab-paclitaxel; patients with a history of mild infusion reactions with paclitaxel who were able to continue to receive paclitaxel with corticosteroid premedication will be eligible to participate, as these cases were likely related to cremaphor and not paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to agents (cyclophosphamide, busulfan, pentostatin, sirolimus, MMF, granulocyte-colony stimulating factor [G-CSF]) used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to defactinib, pembrolizumab, gemcitabine, or other agents used in the studyXx_NEWLINE_xXSubject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PROSTVAC or ipilimumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sertralineXx_NEWLINE_xXKnown severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib or everolimusXx_NEWLINE_xXHistory of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents (R-CHOP) used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to INC280; excipients in the current formulation include microcrystalline cellulose, mannitol, sodium starch glycolate, magnesium stearate and colloidal silicon dioxideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or TMZXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX-200 or other agents used in the study (e.g., imidazoles, quinolones)Xx_NEWLINE_xXPatient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or docetaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or lenalidomide agents used in study, such as bortezomib or thalidomide, in addition to patients with known allergy to sulfobutyl ether beta-cyclodextrin (Captisol)Xx_NEWLINE_xXKnown hypersensitivity or allergic reactions attributed to any compounds of similar chemical or biologic composition to the study medication, such as recombinant IL-12 or other monoclonal antibodiesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Combotox or other agents used in study agentsXx_NEWLINE_xXHistory of allergic reactions or sensitivity to pyrimethamineXx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, anetumab ravtansine or paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MTX110 or gadolinium.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib, mirvetuximab soravtansine or monoclonal antibodiesXx_NEWLINE_xXHistory of allergic reactions attributed to compound of similar chemical or biologic composition to the agents used in this study.Xx_NEWLINE_xXHistory of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to olaparib or its excipientsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide, CRLX101, or other agents used in study.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the regimenXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents to be used in the cohort the subject will be enrolled intoXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel or avelumab, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0 grade >= 3)Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, gemcitabine, pegylated compounds, or other agents used in the studyXx_NEWLINE_xXHistory of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cellsXx_NEWLINE_xXHypersensitivity to chemotherapy or history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, ibrutinib, ICE, Ave, or UtoXx_NEWLINE_xXHas a history of allergic reactions attributed to the study treatments (AZD9150 or durvalumab), assigned chemotherapy agents, their compounds, or agents of similar chemical or biologic composition (e.g., antibody therapeutics)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients.Xx_NEWLINE_xXHistory of significant allergic reactions attributed to compounds of similar composition to SD-101 or BMS-986178Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to apatinib or pembrolizumabXx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in studyXx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in studyXx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, cisplatin (for cohort 1), or cetuximab (for cohort 2)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents on this trialXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to the study vaccine components and any of the chemotherapy drugs (docetaxel, carboplatin, trastuzumab, pertuzumab)Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat, ruxolitinib, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in studyXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to anti-LAG-3, anti-CD137, and anti-PD1 are ineligible; the investigator brochures can be referenced for more informationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent or accompanying supportive medications.Xx_NEWLINE_xXThe patient has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab and/or nivolumabXx_NEWLINE_xXPatients with history of allergic or toxic reactions attributed to cytarabine or a history of allergic reactions to components of the formulated productXx_NEWLINE_xXPatients with history of allergic or toxic reactions attributed to anthracyclines or a history of allergic reactions to components of the formulated productXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, carboplatin and paclitaxel or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)Xx_NEWLINE_xXHistory of allergic reactions attributed to monoclonal antibodies (grade >= 3)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipientsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to EGF816 or gefitinibXx_NEWLINE_xXSubjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to IACS-010759.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to leuprolide acetate, abiraterone acetate, prednisone or apalutamide or other agents used in the study.Xx_NEWLINE_xXHistory of known immediate or delayed hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to INCB039110, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO).Xx_NEWLINE_xXHistory of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to avelumab or other agents used in the study (or monoclonal antibodies)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Vicinium or durvalumab or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab unless felt to be in the best interests of the patient in the opinion of the investigatorXx_NEWLINE_xXPatient must not have a history of allergic reactions like anaphylaxis attributed to compounds of similar chemical or biologic composition to meclizine such as antihistamine drugs.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to fostamatinib or paclitaxel; patients who are able to tolerate paclitaxel on a desensitization protocol will be allowedXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or mifepristoneXx_NEWLINE_xXHistory of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AZD8186 or docetaxel or to docetaxel itselfXx_NEWLINE_xXPatients with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or T-DM1Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel or carboplatinXx_NEWLINE_xXKnown severe hypersensitivity to selumetinib or olaparib, their comparators, or combination medications or any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or olaparib, or their comparatorXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomab or pembrolizumab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan, other topoisomerase inhibitors or gadolinium compoundsXx_NEWLINE_xXHistory of severe allergic reactions (as determined by treating physician) attributed to the drugs being used in the studyXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to HMAsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lamivudineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to zydeligXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab (anti-EGFR).Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to anetumab ravtansine or MK-3475 (pembrolizumab)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in cremophor(R) EL (polyoxyethylated castor oil)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, topotecan, gadolinium, or lipidsXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide are not eligibleXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to denosumab are not eligible (i.e. same class of drugs) (Note: prior bisphosphonates are allowed; patients could have received bisphosphonates or be bisphosphonate-naive; patients who were previously on bisphosphonates can be enrolled in the study, as long as they have a wash-out period of 2 weeks prior to registration)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy agents in this study (if necessary)Xx_NEWLINE_xXKnown hypersensitivity to poziotinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to poziotinibXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to mistletoeXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-DOTA-tyr3-octreotide, Octreoscan, 68Ga-octreotide, or 131I-MIBGXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to clarithromycin or taxanesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1127 (varlilumab) and/or nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib or nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or abirateroneXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparibXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible; known hypersensitivity to any excipients of pembrolizumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, decitabine or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to hydroxychloroquine or received HCQ in the past six monthsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to fosbretabulinXx_NEWLINE_xXHypersensitivity to BV or history of allergic reaction attributed to compounds of similar chemical or biologic composition of BVXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat or decitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib and blinatumomab or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatinXx_NEWLINE_xXKnown hypersensitivity to compounds of similar chemical composition to BMX-001Xx_NEWLINE_xXKnown allergy to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHas a history of allergic reactions attributed to the study treatments (AZD9150 or MEDI4736), their compounds, or agents of similar chemical or biologic composition (eg, antibody therapeutics)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TVB-2640Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of chemical or biologic composition similar to interferons or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide and/or TG02Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or indomethacinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, cisplatin, carboplatin, or etoposideXx_NEWLINE_xXPatients with known allergy to eggs or to compounds with a similar chemical or biologic composition to PROSTVAC or nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar composition to SD-101 or ibrutinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to daunorubicinXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, carboplatin or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or talazoparibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab including any history of severe allergic reactions to monoclonal antibody therapyXx_NEWLINE_xXPatients with a history of allergic reactions attributed to or intolerance to compounds of similar chemical or biologic composition to either CB-839 or capecitabine; if capecitabine has been received previously, must have tolerated at least an equivalent dose to the dose to be administered at their assigned dose levelXx_NEWLINE_xXKnown severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin and pemetrexedXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexorXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to rebastinib or other agents used in the study (e.g., Cremophor)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomabXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible AND/OR patients who have had prior exposure to compounds of similar chemical or biologic composition to pembrolizumab are not eligibleXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to abiraterone or PDMX1001/niclosamideXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI3475 are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cesium 131 or other agents used in this studyXx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinib and/or paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to fluorouracil (5-FU), leucovorin, irinotecan or oxaliplatin or to compounds of similar chemical or biologic compositionXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent or other agents used in the studyXx_NEWLINE_xXPHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: History of allergic reactions attributed to compounds of similar chemical or biologic composition to CRLX101 and/or olaparib or other agents used in studyXx_NEWLINE_xXHistory of allergic reaction to compounds of similar chemical or biologic composition to cytarabineXx_NEWLINE_xXKnown hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to IRX5183Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or irinotecanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib and brentuximab vedotin (BV)Xx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition as obinutuzumab or ibrutinib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumab or nab-paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinibXx_NEWLINE_xXKnown allergy to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to methotrexate, vinblastine, doxorubicin or cisplatin or other agents used in the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib, temozolomide, or dacarbazineXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to DHEA or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine or bevacizumabXx_NEWLINE_xXHistory of allergic reactions attributed to thalidomide, lenalidomide, or other compounds of similar chemical or biologic composition to pomalidomide or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)Xx_NEWLINE_xXHistory of allergic reactions attributed to Noni or other compounds of similar chemical or biologic composition to Noni, or the inactive components present in Noni capsules; uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any psychological, familial, sociological or other concomitant condition that would not allow adequate compliance with the study protocolXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the studyXx_NEWLINE_xXA history of allergic reaction attributed to compounds of similar chemical or biologic composition to fluorouracil (5FU), oxaliplatin, or leucovorinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxelXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or bortezomibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, methotrexate, gemcitabine or other agents used during the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523, gemcitabine, nab-paclitaxel, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to dexrazoxane or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, paclitaxel or carboplatinXx_NEWLINE_xXSubjects with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to DS3032bXx_NEWLINE_xXPHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in studyXx_NEWLINE_xXPHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to doxorubicin or Doxil.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to methoxyamine or to pemetrexed or cisplatinXx_NEWLINE_xXHistory of allergic reactions, intolerance or hypersensitivity attributed to compounds of similar chemical or biologic composition to TRC105 and/or everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugsXx_NEWLINE_xXDocumented allergic reactions or similar to antibody treatmentsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological componentXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to leflunomide or cholestyramineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in studyXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736, olaparib, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthmaXx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736, olaparib or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthmaXx_NEWLINE_xXPHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHistory of allergic reactions (known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma) attributed to compounds of similar chemical or biologic composition to MEDI4736, olaparib, or to other humanized monoclonal antibodiesXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthmaXx_NEWLINE_xXHistory of allergic reaction attributed to compound(s) of similar chemical or biologic composition as ARQ 092, carboplatin, paclitaxel, or anastrozoleXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to indoximod, docetaxel, or other agents used in the study.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvecXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimenXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ABRAXANE or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexedXx_NEWLINE_xXPatients with history of allergic reactions attributed to compounds of similar chemical; or biologic composition to vorinostat or temsirolimus are not eligibleXx_NEWLINE_xXHistory of hypersensitivity reaction specifically attributed to compounds of similar chemical or biologic composition to 5-FU, leucovorin, capecitabine or bevacizumabXx_NEWLINE_xXPropensity to allergic reactions defined as a history of allergic reaction to more than one medicationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdRXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin C or other agents used in the studyXx_NEWLINE_xXPrior allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or trametinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to basiliximabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or metforminXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VOR or HCQXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipientsXx_NEWLINE_xXHistory of allergic reactions attributed to Flagyl (metronidazole), which has a chemical structure similar to EF5Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or ziv-afliberceptXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine and or busulfan or other agents used in this studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatinXx_NEWLINE_xXHistory of known immediate or delayed hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to AT13387, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to etoposideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar biologic composition to M032 or to IL-12Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to propranololXx_NEWLINE_xXHistory of allergic reactions to compounds of similar composition to either CDX-301 or poly-ICLCXx_NEWLINE_xXHistory of prior allergic reactions attributed to compounds of similar chemical or biologic composition as capecitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, oxaliplatin, irinotecan or gemcitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, docetaxel, vorinostat, or granulocyte colony-stimulating factor (G-CSF)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to anakinra or other agents used in study; known hypersensitivity to Chinese hamster ovary (CHO)-cell derived biologics or any components of anakinraXx_NEWLINE_xXHistory of allergic reactions attributed to metformin or other biguinidesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to DOPC, Magnevist, or fluorodeoxyglucose (FDG)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin for patients who will receive chemotherapyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdRXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the experimental agents or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9291 (osimertinib) or bevacizumabXx_NEWLINE_xXNo history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, lomustine, vincristine (vincristine sulfate) or cyclophosphamideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to metforminXx_NEWLINE_xXEXCLUSION CRITERIA FOR REGISTRATION: history of allergic reactions attributed to compounds of similar chemical or biologic composition to metforminXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to Valproic AcidXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and durvalumab or previous toxicity attributed to durvalumab or other PD-1 or PD-L1 directed therapy that led to drug discontinuationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PMXx_NEWLINE_xXHistory of severe allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to STA-9090 (eg. Polyethylene glycol [PEG] 300 and Polysorbate 80)Xx_NEWLINE_xXHistory of allergic reactions to compounds of similar chemical or biologic composition to talactoferrin or the chemotherapy drugsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to IHL-305Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cenersen.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib and/or nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) or other agents used in studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorolanib, nivolumab, or pembrolizumab (as applicable), any monoclonal antibody, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CPI-613 or docetaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifenXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil or imiquimodXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CPI-613Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition;Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs; patients who have previously received either clofarabine or bortezomib will be excludedXx_NEWLINE_xXHistory of allergic reactions to cetuximab.Xx_NEWLINE_xXPatients with known hypersensitivity to nintedanib or 5-azacitidine or who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or 5-azacitidine are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinibXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to BMS-813160, nivolumab, gemcitabine, paclitaxel, nab-paclitaxel, or other agents used in the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab or any excipient or any egg productsXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to MCS110, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or PDMX1001/niclosamideXx_NEWLINE_xXA history of allergic reactions or significant toxicity attributed to compounds of similar chemical or biologic composition to anti-CD20 mAbs, anti-PD-1 mAbs, or TLR agonists.Xx_NEWLINE_xXParticipants who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to birinapant or its constituentsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to regorafenib or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to WP1066Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX970), cisplatin, or gemcitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or sorafenibXx_NEWLINE_xXPatients with a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 are ineligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nelfinavirXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to measles virus vaccinationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and AT13387 used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to XL184Xx_NEWLINE_xXSubjects with history of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 or carfilzomib, lenalidomide, or dexamethasoneXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAL101553 are ineligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this studyXx_NEWLINE_xXHistory of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX3397 or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to quinacrine, capecitabine or fluorouracilXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or vistusertibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to tazemetostatXx_NEWLINE_xXPatients with a known hypersensitivity to olaparib or any of the excipients of the product; history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102 or TMZXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib, carboplatin, cisplatin, or etoposideXx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition to either paclitaxel or ricolinostat; patients who require administration of paclitaxel through a desensitization procedure are not eligible for this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib and MM-398; if patients have a history of allergic reactions to compounds resembling MM-398, they will be excluded from participating in the FMX MRI study, if applicableXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, carboplatin, gemcitabine or to these specific compoundsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-afliberceptXx_NEWLINE_xXPatients who have exhibited allergic reactions to compounds structurally similar to APTO-253 HCIXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or cisplatinum or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to briciclibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs (e.g. cisplatin, paclitaxel)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or belinostatXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions to compounds with similar biologic or chemical composition to pembrolizumab or radium-223Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1401 or CDX-301 or poly-ICLCXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CYT107Xx_NEWLINE_xXHistory of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to metformin, ritonavir or any of their ingredientsXx_NEWLINE_xXHave history of allergic reactions attributed to compounds of similar chemical or biologic composition to taxanes (docetaxel or paclitaxel) or cyclophosphamideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (Escherichia [E] coli producing cell line), plerixafor or busulfanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ethacrynic acid or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Dex or EnzaXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (E. coli producing cell line) and plerixaforXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to either 5-FU/capecitabine or interferonXx_NEWLINE_xXPatients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775Xx_NEWLINE_xXPHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or cyclosporine A or their excipientsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TPI 287Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 or bevacizumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel or enzalutamideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to HDACI, TLR-agonist, or patients with known history of pre-existing auto-immune diseaseXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to INCB024360, MELITAC 12.1, or other vaccine componentsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or ipilimumabXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib, bortezomib or decitabine that are not easily managedXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PF-04449913Xx_NEWLINE_xXNo history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, temozolomide and dacarbazineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostatXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to digoxinXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition ipilimumab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib, erlotinib or gemcitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition (i.e. ethanol) to XL888 or vemurafenib (i.e., ethanol)Xx_NEWLINE_xXPatients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the studyXx_NEWLINE_xXPHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition of decitabine, cytarabine or daunorubicinXx_NEWLINE_xXHistory of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition of those used in this studyXx_NEWLINE_xXPatient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-12 or other agents used in studyXx_NEWLINE_xXKnown history of allergic reactions to paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib (ABT-888) or cyclophosphamide used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to riluzole or sorafenibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (i.e. thalidomide)Xx_NEWLINE_xXPoor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib and/or dexamethasoneXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib and/or cetuximabXx_NEWLINE_xXPatients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocolXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to afatinibXx_NEWLINE_xXPoor tolerability or known allergy to lenalidomide, bortezomib and/or dexamethasone or compounds that have similar chemical or biologic composition to these study drugsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanibXx_NEWLINE_xXPatient must have no history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatinXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991, cetuximab, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatinXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD 1775 (MK-1775) or gemcitabineXx_NEWLINE_xXHistory of Grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition as MSC2363318AXx_NEWLINE_xXSubjects with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin. Compounds of similar composition include Auristatin PHE as an anti-fungal agent, Auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and Symplostatin 1 as an anti-tumor agent.Xx_NEWLINE_xXSUB-PROTOCOL AIM A: History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibioticsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, or other agents used in the study.Xx_NEWLINE_xXNo history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib, lenalidomide or rituximab or hypersensitivity to murine proteins or to any component of rituximabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or rapamycinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin-C or 5-fluorouracilXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or HCQXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to daunorubicin or cytarabineXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736 or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds or similar chemical or biological composition to ibrutinibXx_NEWLINE_xXHistory of allergic reactions attributable to compounds of similar chemical or biologic composition to ibrutinib or any component of pneumococcal, influenza and DTaP vaccinesXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to mocetinostat or brentuximab vedotinXx_NEWLINE_xXHistory of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, Taxotere, Xeloda, cisplatin, or irinotecanXx_NEWLINE_xXPatients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managedXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to hydroxychloroquineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dacomitinibXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or any of the components of the vaccine being administered as part of this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, bortezomib or rituximabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to metformin or oxaliplatin or fluorouracil (5-FU)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 or decitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab; prior hypersensitivity reactions to anti-CD20 therapy or anti-CD30 therapy is not an exclusion criterionXx_NEWLINE_xXHistory of allergic reaction(s) attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatinXx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab or other agents used in this studyXx_NEWLINE_xXPatients who have a history of allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and/or humanized antibodies are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or atezolizumabXx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or lenalidomideXx_NEWLINE_xXPatients with a history of allergic reactions attributed to bevacizumab or to compounds of similar chemical or biologic composition to nivolumab or bevacizumab are excludedXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, cytarabine, bendamustine or other agents used in the studyXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-JR11 as assessed from medical recordsXx_NEWLINE_xXPrior allergic reactions attributed to other monoclonal antibodiesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MGEXx_NEWLINE_xXSubjects with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the productXx_NEWLINE_xXSubjects with a history of hypersensitivity to compounds of similar biologic composition to durvalumab or any constituent of the productXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 are not eligible; known hypersensitivity to any excipients of MK-3475Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to GEN-1 or other agents used in this study.Xx_NEWLINE_xXKnown allergy to any of the treatment components including a history of allergic reactions attributed to compounds of chemical or biological composition similar to olaratumab.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib and/or bazedoxifeneXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PM01183 or trabectedin (Yondelis, ET-743)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipientsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9150Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to KPT-330 or other agents used in the studyXx_NEWLINE_xXPoor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitolXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or other agents used in the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to tosedostat or capecitabine or other agents used in the studyXx_NEWLINE_xXParticipants may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparibXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXPatient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PBI-05204 (i.e., cardiac glycoside compounds).Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, including but not limited to established allergic reaction to benzodiazepines, 5-FU (fluorouracil), leucovorin (leucovorin calcium) or oxaliplatinXx_NEWLINE_xXPatients with a history of allergic reactions attributed to eribulin or irinotecanXx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXPatient has a history of allergic reactions to compounds of similar chemical or biological composition to buparlisibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, cetuximab, and/or bevacizumab that led to discontinuation of those agentsXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to elotuzumab or lenalidomideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or omega-3 fatty acidsXx_NEWLINE_xXPatient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475Xx_NEWLINE_xXPrior treatment with or allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinibXx_NEWLINE_xXPatients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine or temsirolimusXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus or perifosineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to crizotinib or enzalutamideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine and eribulinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to X-82, docetaxel, or granulocyte colony stimulating factorsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to LDE 225 or everolimus in the study or other rapamycin analogs (e.g. sirolimus, temsirolimus)Xx_NEWLINE_xXHistory of severe allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or idelalisibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin or docetaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to curcumin or vitamin D or other agents used in this studyXx_NEWLINE_xXPatients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managedXx_NEWLINE_xXHistory of allergic reactions or idiosyncrasy attributed to progestins or compounds of similar chemical structure to sodium cridanimod or lidocaine;Xx_NEWLINE_xXResearch participants with a history of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximabXx_NEWLINE_xXPatients with known grade 2 or greater allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone, carboplatin, or gemcitabine are ineligible for study enrollmentXx_NEWLINE_xXPHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinibXx_NEWLINE_xXPHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions to compounds of similar chemical or biological composition to T DM1 or ONT-380, except for a history of Grade 1 or Grade 2 Infusion Related Reaction to trastuzumab which has been successfully managed.Xx_NEWLINE_xXPoor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib, panobinostat and/or dexamethasoneXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, or nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to fluoropyrimidine (e.g., capecitabine, fluorouracil, fluorodeoxyuridine) or tetrahydrouridineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib.Xx_NEWLINE_xXKnown hypersensitivity to 5-fluorouracil or to any component of the investigational products or compounds of similar chemical compositionXx_NEWLINE_xXParticipants who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib or fulvestrantXx_NEWLINE_xXHistory of allergic reactions attributed to lenalidomide or compounds of similar chemical or biologic composition to lenalidomide including thalidomideXx_NEWLINE_xXPART B: History of allergic or severe reactions attributed to compounds of similar chemical or biologic composition to ponatinibXx_NEWLINE_xXHistory of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80Xx_NEWLINE_xXHistory of grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition to ARRY-380 or trastuzumabXx_NEWLINE_xXHistory of allergic reaction attributed to compounds of similar chemical or biologic composition to eribulin mesylate, trastuzumab or pertuzumab, which cannot be managed by premedicationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this studyXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or lenalidomideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib or enzalutamideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia vaccine)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia vaccine)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922Xx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to midostaurin and/or decitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabineXx_NEWLINE_xXPatients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouricil, irinotecan, oxaliplatin, or losartanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, trastuzumab, pertuzumab; patients with minor (grade 1 or 2) allergic reactions to these agents, controlled with standard supportive measures, are eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to, or intolerance of, or other significant toxicity with, compounds of similar chemical or biologic composition to X-82 or everolimusXx_NEWLINE_xXREGISTRATION EXCLUSION CRITERIA: History of allergic reactions attributed to compounds of similar chemical or biologic composition to trastuzumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition as ARQ 087Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (including thalidomide), clarithromycin, or melphalanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to FLTXx_NEWLINE_xXPatient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib, cetuximab, or other agents used in the studyXx_NEWLINE_xXPatients must not have any of the following conditions:\r\n* Recent major surgery, hormonal therapy (other than replacement) or chemotherapy, within 4 weeks prior to entering the study or those who have not recovered from the adverse events of treatment\r\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy on this trialXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy used in the studyXx_NEWLINE_xXPatient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to either MLN8237 or nab-paclitaxel, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 386 or the anti-VEGF agent used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to 5FU, leucovorin, irinotecan or oxaliplatin or to compounds of similar chemical or biologic composition.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dexanabinolXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan or irinotecanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to black cohoshXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostatXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or abirateroneXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to fulvestrant or ganetespibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to fluorouracil (5-FU), capecitabine, oxaliplatin, leucovorin, bevacizumab, and/or vitamin D3Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib (or to capecitabine for cohorts 3a/3b)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine and hydroxychloroquine (HCQ)Xx_NEWLINE_xXAcute allergic disorders or a history of severe allergic reactionsXx_NEWLINE_xXSubjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the studyXx_NEWLINE_xXHistory of allergy or reaction attributed to compounds of chemical or biologic composition similar to those of MEDI-573 or AIXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sonidegib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to plerixafor or bevacizumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition of BKM120, BYL719, capecitabine (including fluorouracil), trastuzumab or lapatinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to lapatinib or trastuzumab; however, patients with a history of infusion reaction to trastuzumab which was controlled with premedication on subsequent infusions without a recurring infusion reaction are eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232Xx_NEWLINE_xXHistory of allergic reactions to palbociclib or attributed to compounds of similar chemical or biologic composition to palbociclibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib maleate or olaparibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PF-00299804Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds similar in chemical or biological composition to vorinostat or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in studyXx_NEWLINE_xXKnown or suspected allergy to any recombinant human antibodies, or compounds of similar chemical or biologic composition to sorafenib or any of the drugs in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN673 (talazoparib)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ganetespib or other agents used in study; history of severe allergic or hypersensitivity reactions to taxanesXx_NEWLINE_xXPatients with a history of serious allergic reactionsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or idarubicin or cytarabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, 5-FU, leucovorin or any of the products to be administered during dosingXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to platinums, taxanes or fluoropyrimidinesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or belinostatXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan or selinexorXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar composition to SD-101 or ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] antibodies)Xx_NEWLINE_xXPrior allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-1775 or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib or clindamycin (topical agent for potential skin toxicity)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEK162, anthracycline, or cytarabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, mannitol, irinotecan, docetaxel, pemetrexed, or gemcitabine, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Sunphenon 90 DCF-T or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 3-AP (triapine) or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to tretinoin or lithium carbonate or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 or other agents used in this studyXx_NEWLINE_xXSubjects with history of hypersensitivity to compounds of similar chemical or biologic composition of XILONIX.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to peg-IFN?-2bXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin and paclitaxel or other agents used in the study are excludedXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to SS1(dsFv)PE38Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide, gemcitabine or carboplatin, or other agents used in studyXx_NEWLINE_xXERLOTINIB HYDROCHLORIDE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (erlotinib hydrochloride)Xx_NEWLINE_xXSELUMETINIB ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 (selumetinib)Xx_NEWLINE_xXAKT INHIBITOR MK2206 ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 (Akt inhibitor MK2206)Xx_NEWLINE_xXLAPATINIB DITOSYLATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinibXx_NEWLINE_xXSUNITINIB MALATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MPDL3280A, carboplatin, or paclitaxelXx_NEWLINE_xXPatient with history of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to enzalutamide, carboplatin, or paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib and/or onalespibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to onalespib or AT7519MXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or temsirolimusXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to calcitriol, ketoconazole, or other agents used in studyXx_NEWLINE_xXPatients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to belinostat, including hydroxamate compounds or arginineXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin; compounds of similar composition include auristatin PHE as an anti-fungal agent, auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and symplostatin 1 as an anti-tumor agentXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonateXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, oxaliplatin, fluorouracil (5-FU), docetaxel, or irinotecanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dinaciclib or to MK-2206Xx_NEWLINE_xXPatients with history of allergic reactions attributed to compounds of similar composition to sirolimus, cyclophosphamide, or topotecan are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to components of the formulated product(s)Xx_NEWLINE_xXHistory of allergic reactions attributed to compound of similar chemical or biologic composition to the agent(s) used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, or nab-paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to the agent used in study.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) or other agents used in this studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or R-ICEXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MVA-brachyury-TRICOM or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanibXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan HCl for injection (propylene glycol-free), Captisol, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide, everolimus, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206Xx_NEWLINE_xXKnown hypersensitivity/history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or fulvestrant.Xx_NEWLINE_xXHistory of allergic or toxic reactions attributed to cytarabine (Part 2) or history of allergic reactions to components of the formulated productXx_NEWLINE_xXKnown hypersensitivity to ipilimumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Cabazitaxel, or to drugs formulated with polysorbate 80.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximabXx_NEWLINE_xXPatient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to levocetirizine, capecitabine, bevacizumab, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition as TG02 citrate.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD-101 or Zevalin or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pioglitazoneXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib and ipilimumabXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or AZD1775 (MK-1775) are ineligible; the AZD1775 (MK-1775) investigator brochure and the temozolomide package insert can be referenced for more informationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib and its excipients.Xx_NEWLINE_xXKnown severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ARQ 197 or temsirolimusXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib or leflunomideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, including but not limited to established allergic reaction to benzodiazepinesXx_NEWLINE_xXContraindication to steroid use or history of allergic reactions attributable to the study compoundsXx_NEWLINE_xXHistory of allergic reactions to monoclonal antibodiesXx_NEWLINE_xXPatients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to RAD001 or SOM230 (pasireotide)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents used in study (including hypersensitivity to paclitaxel, Cremophor, or platins)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or hydroxychloroquineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds chemically related to lapatinib (quinazolines), capecitabine, fluorouracil or any excipients;Xx_NEWLINE_xXThe participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of cixutumumab or to octreotideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvecXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the studyXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to volasertib or VSLI are not eligibleXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to rociletinib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN 673 and AT13387 used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan, cyclophosphamide, or other agents used in the studyXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed (pemetrexed disodium), 5-FU (fluorouracil), leucovorin (leucovorin calcium) or oxaliplatin, or other agents used for premedication in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, nab-paclitaxel or temozolomideXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to donepezil; hypersensitivity to donepezilXx_NEWLINE_xXHistory of allergic reaction attributed to compounds of similar chemical or biologic composition to paclitaxel, which cannot be managed by premedicationXx_NEWLINE_xXPatients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic compositionXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and interferon-gamma; patients who are hypersensitive to Escherichia (E). coli are also excludedXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin mesylate or pembrolizumabXx_NEWLINE_xXHistory of allergic reactions attributed to tamoxifen or compounds of similar chemical or biologic compositionXx_NEWLINE_xXSubject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.Xx_NEWLINE_xXHistory of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab; known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 NCI CTCAE version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CUDC-907Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide, abiraterone acetate, or other study drugsXx_NEWLINE_xXPatients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sildenafil or phosphodiesterase-5 (PDE5) inhibitors such as vardenafil (Levitra) and tadalafil (Cialis) are not eligible.Xx_NEWLINE_xXSubjects with known hypersensitivity or other allergic reactions attributed to compounds of similar biologic composition to netupitant, palonosetron, dexamethasone, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to amide local anesthetics, acetaminophen or dexamethasoneXx_NEWLINE_xXHistory of allergic reactions to whey proteinXx_NEWLINE_xXHistory of severe (i.e. anaphylactic) allergic reactions attributed to compounds of similar chemical or biologic composition to glucocorticoids and other component of R-Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cadaveric component, i.e. Flex HDXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel not responsive to traditional desensitization proceduresXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Adriamycin, dacarbazine, or brentuximabXx_NEWLINE_xXHistory of hypersensitivity attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or osimertinib (AZD9291)Xx_NEWLINE_xXKnown sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition entinostat, nivolumab, or ipilimumab; history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to naltrexoneXx_NEWLINE_xXNo investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or deviceXx_NEWLINE_xXPatient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin or other agents used in the studyXx_NEWLINE_xXPatient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonateXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinibXx_NEWLINE_xXHistory of allergic reactions to yeast or attributed to compounds of similar chemical or biologic composition to Gardasil 9 HPV vaccineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestaneXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (Tarceva)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to 4-OHT gelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to INO-8000 and INO-9012Xx_NEWLINE_xXHistory of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin (i.e., other statin medications)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to NeuVaxXx_NEWLINE_xXHistory of allergic reaction to aspirin or attributed to compounds of similar chemical or biologic composition to aspirin, including other nonsteroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXHistory of allergic reaction to zileuton or attributed to compounds of similar chemical or biologic composition to zileutonXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MUC1/Poly?ICLCXx_NEWLINE_xXHistory of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin (i.e., other statin medications)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to WOKVACXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AvmacolXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to bexarotene gel, oral or topical retinoidsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Gardasil or Gardasil 9Xx_NEWLINE_xXHistory of allergic reactions or intolerance attributed to aspirin or compounds of similar chemical or biologic compositionXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea or EGCGXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MerivaXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of alendronate and other bisphosphonatesXx_NEWLINE_xXDocumented history of allergic reactions attributed to compounds of similar chemical or biologic composition to buproprionXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to aspirinXx_NEWLINE_xXParticipants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of iloprostXx_NEWLINE_xXHistory of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to pravastatin (i.e., other statin medications)Xx_NEWLINE_xXHistory of allergic reactions or hypersensitivity attributed to denosumab or any components of denosumab or compounds of similar chemical or biologic composition to denosumab, such as other RANKL inhibitorsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to Polyphenon E (or green tea), or intravenous contrast that is required for CT scanXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition of PROSTVACXx_NEWLINE_xXParticipants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to berberine will be excludedXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to metformin or prior use of metformin within the last yearXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to telapristone (i.e. other progesterone antagonists)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PFEXx_NEWLINE_xXA history of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifenXx_NEWLINE_xXHistory of allergic reactions attributed to naproxenXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Polyphenon E, tea, or any of the inactive ingredients present in the active or placebo drug products, including gelatin capsulesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to the study agentsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical composition to YF476Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition of GARDASIL 9 (recombinant human papillomavirus nonavalent vaccine), including yeast allergyXx_NEWLINE_xXHistory of allergic reactions attributed to aspirin or compounds of similar chemical or biologic composition to the study agentXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to aspirin, NSAIDs, cyclooxygenase-2 (COX2) inhibitorsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agentXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabazitaxel or other drugs formulated with polysorbate 80; or abiraterone acetateXx_NEWLINE_xXHistory of allergic reactions or hypersensitivity to compounds similar to trastuzumab and/or letrozoleXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) are ineligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to romidepsin, including cyclic tetrapeptide compoundsXx_NEWLINE_xXHave a history of allergic reactions to metformin or similar drugsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to DHA or corn/soy oil in placebo agentXx_NEWLINE_xXHistory of allergic reaction to aspirin or attributed to compounds of similar chemical or biologic composition to aspirin, including other nonsteroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotideXx_NEWLINE_xXParticipants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoidsXx_NEWLINE_xXPatient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FESXx_NEWLINE_xXPatient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to PBRXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or FMISOXx_NEWLINE_xXThere will be no exclusion requirements due to co-morbid disease or incurrent illness\r\n* History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the studyXx_NEWLINE_xXHistory of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the studyXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FLT or FDG are NOT eligibleXx_NEWLINE_xXPatients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNPXx_NEWLINE_xXPatients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FES are NOT eligible.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to demeclocyclineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in studyXx_NEWLINE_xXSURGICAL ARM: history of allergic reactions attributed to compounds of similar chemical or biologic composition to tetracyclinesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to copper Cu 64 anti-CEA monoclonal antibody M5A (64Cu-M5A)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytolXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to magnetic resonance (MR) contrast materialXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the studyXx_NEWLINE_xXHistory of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biologic composition to Ga-68-DOTA-TOC or 18F-FLT used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to FDHTXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to L-[methyl-11C]methionineXx_NEWLINE_xXHistory of allergic reactions to INCB062079, any of the excipients of INCB062079 or similar compounds.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lorlatinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid (ALA)Xx_NEWLINE_xXWomen with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to isosulfan blue or indocyanine green or other agents used in this studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ALA; patients should refrain from use of other potential phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) for 72 hXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to EovistXx_NEWLINE_xXHistory of allergic reactions to compounds of similar chemical composition to ALAXx_NEWLINE_xXHistory of allergic reaction to compounds of similar composition to ferumoxytol (e.g. IV iron)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin DXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to idelalisibXx_NEWLINE_xXHistory of allergic reactions attributed to 5 azacitidineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in studyXx_NEWLINE_xXThe participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or cisplatin.Xx_NEWLINE_xXThe participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or carboplatin.Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, or blinatumomabXx_NEWLINE_xXHistory of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to CE/BZA; (I.e. same class of drug as CE/BZA)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab.Xx_NEWLINE_xX